248 related articles for article (PubMed ID: 31578579)
1. Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma.
Shimbo A; Kajiyama H; Tamauchi S; Yoshikawa N; Ikeda Y; Nishino K; Suzuki S; Niimi K; Sakata J; Kikkawa F
Oncol Rep; 2019 Dec; 42(6):2323-2332. PubMed ID: 31578579
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
Qiu JJ; Lin XJ; Tang XY; Zheng TT; Zhang XY; Hua KQ
Int J Cancer; 2020 May; 146(9):2588-2598. PubMed ID: 31577838
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
4. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
5. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
[TBL] [Abstract][Full Text] [Related]
6. Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M; Zhang S; Ma Y; Yang Y; An R
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33846814
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion.
Barbolina MV; Adley BP; Kelly DL; Shepard J; Fought AJ; Scholtens D; Penzes P; Shea LD; Stack MS
Int J Cancer; 2009 Aug; 125(4):816-25. PubMed ID: 19382180
[TBL] [Abstract][Full Text] [Related]
8. Silencing the long noncoding RNA, TINCR, a molecular sponge of miR‑335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression.
Li R; Wang Y; Xu Y; He X; Li Y
Int J Oncol; 2019 Nov; 55(5):1110-1124. PubMed ID: 31545411
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
10. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
[TBL] [Abstract][Full Text] [Related]
11. Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells.
Wang F; Zhang L; Liu J; Zhang J; Xu G
Aging (Albany NY); 2020 Jun; 12(11):11042-11060. PubMed ID: 32516753
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.
Xia B; Lin M; Dong W; Chen H; Li B; Zhang X; Hou Y; Lou G
J Biochem Mol Toxicol; 2018 Aug; 32(8):e22168. PubMed ID: 30004169
[TBL] [Abstract][Full Text] [Related]
13. High expression of TRIM24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer.
Zhang L; Chen H; Ding B; Jiang W
J Ovarian Res; 2022 Feb; 15(1):19. PubMed ID: 35105347
[TBL] [Abstract][Full Text] [Related]
14. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
[TBL] [Abstract][Full Text] [Related]
15. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
[TBL] [Abstract][Full Text] [Related]
16. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
17. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
[TBL] [Abstract][Full Text] [Related]
18. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
19. KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear‑cell carcinoma cells.
Kawai Y; Shibata K; Sakata J; Suzuki S; Utsumi F; Niimi K; Sekiya R; Senga T; Kikkawa F; Kajiyama H
Oncol Rep; 2018 Jul; 40(1):195-205. PubMed ID: 29749467
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer.
Han GH; Chay DB; Nam S; Cho H; Chung JY; Kim JH
BMC Cancer; 2019 Dec; 19(1):1202. PubMed ID: 31823759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]